GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzymatica AB (OSTO:ENZY) » Definitions » Net Income (Continuing Operations)

Enzymatica AB (OSTO:ENZY) Net Income (Continuing Operations) : kr-52.32 Mil (TTM As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Enzymatica AB Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Enzymatica AB's Net Income (Continuing Operations) for the three months ended in Mar. 2025 was kr-18.01 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 was kr-52.32 Mil.


Enzymatica AB Net Income (Continuing Operations) Historical Data

The historical data trend for Enzymatica AB's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymatica AB Net Income (Continuing Operations) Chart

Enzymatica AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.22 -45.39 -68.66 -49.73 -53.18

Enzymatica AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.86 -13.79 -7.25 -13.28 -18.01

Enzymatica AB Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-52.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzymatica AB  (OSTO:ENZY) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Enzymatica AB Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Enzymatica AB's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzymatica AB Business Description

Industry
Traded in Other Exchanges
N/A
Address
Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.

Enzymatica AB Headlines

From GuruFocus

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson 12-07-2015

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi 12-20-2016

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon 07-01-2016